Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 clients • 5 examiners • 3 art units • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sheppard Mullin Richter & Hampton LLP-Ionis Pharm has 5 pending office actions in Biotechnology & Pharmaceuticals. The record attributes 14771 career applications, a figure that supplies application-history context for this profile.
The resolved allowance rate is 87.12%, and allowed matters averaged 3.19 office actions per allowance. Those measures describe resolved prosecution outcomes and the action activity associated with allowances, respectively. Because the profile is tied to Ionis Pharm and retains the broader application-history figure, practitioners should review the current matters separately from the historical outcome indicators.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | DACE DENITO, ALEXANDRA GERALDINE | — |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| IONIS PHARMACEUTICALS, INC. | 4 |
| Ionis Pharmceuticals, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1637 | 3 |
| 1636 | 1 |
| 1600 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | Ionis Pharmaceuticals, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112Other | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | Ionis Pharmaceuticals, Inc. | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | Ionis Pharmceuticals, Inc. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Mar 16, 2023 |
| 17635096 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. | VIVLEMORE, TRACY ANN | 1600 | §103 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | Ionis Pharmaceuticals, Inc. | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial87.1% of resolved applications prosecuted by Sheppard Mullin Richter & Hampton Llp-Ionis Pharm were allowed, across 14,771 applications in USPTO records.
3.19 office actions per allowed application on average.
5 pending office actions as of October 2026, for 2 clients, before 5 examiners in 3 art units.
